Bob Goldman is speaking during the conference on a panel titled “Evaluating Damages for Misappropriation of Technical Trade Secrets.”
For more information on this event, click here.
Biosimilars: Economic Issues for IP Litigation
In July 2021, the U.S. Food and Drug Administration granted a determination of interchangeability to a biosimilar drug for the first time. This approval has...